Review | Qualitya | Glycaemic control | Vascular risk factor control | Retinopathy screening | Foot screening | Renal monitoring | Smoking | |||
---|---|---|---|---|---|---|---|---|---|---|
 |  | Process | Patient | Process | Patient |  |  |  | Process | Patient |
Patient education and support | ||||||||||
Allemann 2009 [26] | 9 | Â | + | Â | Â | Â | Â | Â | Â | Â |
Armour 2005 [27] | 5 | Â | + | Â | Â | Â | Â | Â | Â | Â |
Brown 1990 [30] | 6 | Â | + | Â | + (Lipids), 0 (BP) | Â | Â | Â | Â | Â |
Cooper 2009 [34] | 7 | Â | 0 | Â | Â | Â | Â | Â | Â | Â |
Couch 2008 [35] | 10 | Â | + | Â | Â | Â | Â | Â | Â | Â |
Deakin 2005 [36] | 10 | Â | + | Â | + (BP), 0 (Lipids) | Â | Â | Â | Â | Â |
Duke 2009 [37] | 9 | Â | + | Â | Mixed (BP), O (Lipids) | Â | Â | Â | Â | 0 |
Ellis 2004 [38] | 6 | Â | + | Â | Â | Â | Â | Â | Â | Â |
Gary 2003 [42] | 6 | Â | + | Â | Â | Â | Â | Â | Â | Â |
Hampson 2001 [45] | 8 | Â | + | Â | 0 (Lipids) | Â | Â | Â | Â | Â |
Harkness 2010 [46] | 5 | Â | + | Â | Â | Â | Â | Â | Â | Â |
Hawthorne 2008 [47] | 11 | Â | + | Â | + (Lipids) 0 (BP) | Â | Â | Â | Â | Â |
Loveman 2008 [53] | 7 | Â | + | Â | + (Lipids, BP) | Â | Â | Â | Â | Â |
Loveman 2003 [52] | 8 | Â | + | Â | Mixed (Lipids) + (BP) | Â | Â | Â | Â | Â |
Minet 2010 [55] | 5 | Â | + | Â | Â | Â | Â | Â | Â | Â |
Norris 2005 [60] | 9 | Â | Mixed | Â | 0 (Lipids, BP) | Â | Â | Â | Â | Â |
Norris 2002 [59] | 8 | Â | + | Â | 0 (Lipids, BP) | Â | Â | Â | Â | Â |
Norris 2001 [58] | 5 | Â | + | Â | + (Lipids) 0 (BP) | Â | 0 | Â | Â | Â |
Savage 2010 [65] | 5 | Â | + | Â | Â | Â | Â | Â | Â | Â |
Valk 2001 [69] | 9 | Â | Â | Â | Â | Â | * | Â | Â | Â |
Winkley 2006 [72] | 9 | Â | Mixed | Â | Â | Â | Â | Â | Â | Â |
Telemedicine | ||||||||||
Balas 2004 [28] | 5 | 0 | + | Â | Â | 0 | 0 | Â | Â | Â |
Farmer 2005 [39] | 5 | Â | Mixed | Â | Â | Â | Â | Â | Â | Â |
Liang 2011 [49] | 5 | Â | + | Â | Â | Â | Â | Â | Â | Â |
Montori 2004 [56] | 6 | Â | + | Â | Â | Â | Â | Â | Â | Â |
Polisena 2009 [62] | 8 | Â | Mixed | Â | Â | Â | Â | Â | Â | Â |
Russell 2009 [64] | 5 | Â | + | Â | Â | Â | Â | Â | Â | Â |
Shulman 2010 [67] | 8 | Â | + | Â | Â | Â | Â | Â | Â | Â |
Sutcliffe 2011 [68] | 7 | Â | + | Â | Â | Â | Â | Â | Â | Â |
Verhoeven 2007 [70] | 5 | Â | Mixed | Â | 0 (Lipids, BP) | Â | Â | Â | Â | Â |
Wu 2010 [73] | 7 | Â | + | Â | Â | Â | Â | Â | Â | Â |
Provider role changes | ||||||||||
Alam 2009 [25] | 7 | Â | + | Â | Â | Â | Â | Â | Â | Â |
Clark 2011 [33] | 7 | Â | Â | Unclear | + (BP) | Â | Â | Â | Â | Â |
Lindenmeyer | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
2006 [50] | 7 | 0 | + | Â | Â | 0 | 0 | Â | Â | Â |
Loveman 2003 [51] | 9 | Â | + | Â | Â | Â | Â | Â | Â | Â |
Machado 2007 [54] | 7 | Â | + | Â | + (Lipids, BP) | Â | Â | Â | Â | Â |
Norris 2006 [57] | 6 | 0 | + | Â | 0 (Lipids, BP) | Â | Â | Â | Â | Â |
Wubben 2008 [74] | 6 | Â | + | Â | + (Lipids, BP) | Â | Â | Â | Â | Â |
Organisational changes | ||||||||||
Al-Ansary 2011 [24] | 7 | Â | 0 | Â | Â | Â | Â | Â | Â | Â |
Clar 2007 [32] | 9 | Â | 0 | Â | Â | Â | Â | Â | Â | Â |
Foy 2010 [40] | 7 | Â | + | Â | Â | Â | Â | Â | Â | Â |
Griffin 1998 [44] | 6 | Â | 0 | Â | Â | Â | Â | Â | Â | Â |
Broad based reviews | ||||||||||
Chodosh 2005 [31] | 6 | Â | + | Â | Â | Â | Â | Â | Â | Â |
Glazier 2006 [43] | 5 | Â | + | Â | 0 (Lipids, BP) | 0 | 0 | 0 | Â | Â |
Pimouguet 2011 [61] | 7 | Â | + | Â | Â | Â | Â | Â | Â | Â |
Renders 2001 [63] | 5 | + | + | 0 | 0 (Lipids, BP) | + | 0 | 0 | Â | Â |
Shojania 2006 [16] | 5 | 0 | + | Â | 0 BP | 0 | 0 | Â | Â | Â |
Saxena 2007 [66] | 6 | Â | + | Â | + (Lipids) mixed (BP) | Â | Â | Â | Â | Â |
Vermeire 2005 [71] | 9 | Â | 0 | Â | 0 (Lipids, BP) | Â | Â | Â | Â | 0 |
Zhang 2007 [75] | 7 | Â | Â | Â | Â | + | Â | Â | Â | Â |